Category: EDAP TMS SASyndicate content

ArthroCare executives found guilty of defrauding investors | Medtech legal news for the week of September 1, 2014

September 1, 2014 by MassDevice

Here's a look at some of the top legal news stories for medical device companies this week: ArthroCare ex-CEO faces 30-year sentence for fraud; Shareholders sue Edap following FDA slip; Ex-sales rep wins class action status in lawsuit against Stryker; Another Covidien shareholder sues over Medtronic deal; Respiratory rivals ResMed, BMC each tally wins in Trade Commission ruling

ArthroCare ex-CEO faces 30-year sentence for fraud

August 25, 2014 by Arezu Sarvestani

ArthroCare ex-CEO faces 30-year sentence for fraud

Shareholders sue Edap following FDA slip

August 27, 2014 by Arezu Sarvestani

Lawyers are looking for more shareholders to join a class action lawsuit against Edap TMS after an FDA expert panel vote against the company's ultrasound ablation technology.

Shareholders sue Edap following FDA slip

A law firm is gathering support for a class action lawsuit against Edap TMS (NSDQ:EDAP), accusing leadership of misleading investors after an FDA expert panel panned the company's flagship ablation technology.

Medical device makers find new layer of regulation before earning CE Mark approval | Regulatory news for the week of August 4, 2014

August 5, 2014 by MassDevice

Here's a look at some of the top regulatory stories for medical device companies this week: Medical device makers face new obstacles to European approval; FDA panel narrowly OKs Cohera Medical's TissuGlu; FDA cuts fiscal 2015 user fees; Catching up with the FDA's 2014 guidance; FDA panel votes against EDAP's ultrasound prostate cancer ablation

Medical device makers face new obstacles to European approval

July 30, 2014 by Arezu Sarvestani

Medical device makers face new obstacles to CE Mark

UPDATE: FDA panel votes against Edap's ultrasound prostate cancer ablation

July 31, 2014 by Ingrid Mezo

An FDA advisory panel votes that French device maker Edap failed to demonstrate that its novel Ablatherm prostate cancer treatment is safe and effective.

UPDATE: FDA panel votes against Edap's ultrasound prostate cancer ablation

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

FDA panel votes against EDAP's ultrasound prostate cancer ablation

July 30, 2014 by Ingrid Mezo

The FDA's expert advisory panel votes that French device maker EDAP failed to demonstrate that its novel Ablatherm prostate cancer treatment is safe and effective.

FDA panel rejects EDAP's ultrasound prostate cancer ablation

The FDA's Gastroenterology & Urology Devices panel today voted against recommending approval of EDAP's (NSDQ:EDAP) Ablatherm system for thermal ablation of the prostate gland to treat low-risk, localized prostate cancer.

Press Release: EDAP completes FDA inspection of manufacturing site

June 30, 2014 by MassDevice

Press Release: EDAP completes FDA inspection of manufacturing site

LYON, France -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced that the U.S. Food and Drug Administration (FDA) concluded its routine inspection of EDAP's manufacturing site with no findings nor issuance of Form 483 observations.

EDAP creeps toward FDA approval with clean inspection

June 30, 2014 by Arezu Sarvestani

FDA inspectors find no issues at EDAP's manufacturing facility, putting the company one step closer to winning premarket approval for its ultrasound-based prostate cancer treatment.

EDAP creeps toward FDA approval with clean inspection
Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp